PK-PD of antifungal drugs: from preclinical data to clinical applications

被引：0
|
作者：
Mazzei, T. [1 ]
机构：
[1] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2013年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
下载
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study
    Huang, Anxiong
    Luo, Xun
    Xu, Zihui
    Huang, Lingli
    Wang, Xu
    Xie, Shuyu
    Pan, Yuanhu
    Fang, Shiwei
    Liu, Zhenli
    Yuan, Zonghui
    Hao, Haihong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Investigational drugs for fracture healing: preclinical & clinical data
    Klontzas, Michail E.
    Kenanidis, Eustathios I.
    MacFarlane, Robert J.
    Michail, Theodoros
    Potoupnis, Michael E.
    Heliotis, Manolis
    Mantalaris, Athanasios
    Tsiridis, Eleftherios
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 585 - 596
  • [23] PK-PD parameters ratio of antibiotics released from antibiotic-loaded spacers in drainage fluids
    Minelli, E. Bertazzoni
    Benini, A.
    Magnan, B.
    Bartolozzi, P.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S384 - S384
  • [24] How population PK/PD improves the evaluation and clinical use of veterinary drugs
    Laffont, C. M.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2012, 35 : 16 - 16
  • [25] PK-PD Analysis of PASI with Data at Boundary: BI 655066 an Anti-IL-23A mAb for the Treatment of Psoriasis
    Lalovic, Bojan
    Rogers, James
    French, Jonathan
    Flack, Mary
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S64 - S64
  • [26] DETERMINING THE OPTIMAL DOSE OF MOXIDECTIN FOR ONCHOCERCIASIS VIA PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELLING OF DATA FROM HEALTHY VOLUNTEERS AND PATIENTS WITH ONCHOCERCIASIS
    Jamsen, Kris
    Kirkpatrick, Carl
    Opoku, Nicholas O.
    Attah, Simon K.
    Awadzi, Kwablah
    Kuesel, Annette C.
    Olliaro, Piero
    Olipoh, George
    Ryg-Cornejo, Victoria
    Tan, Beesan
    Sullivan, Mark
    Fleckenstein, Lawrence
    Rayner, Craig
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 238 - 239
  • [27] Tailor-made drug treatment for children Creation of an infrastructure for data-sharing and population PK-PD modeling
    Ince, Ibrahim
    de Wildt, Saskia N.
    Tibboel, Dick
    Danhof, Meindert
    Knibbe, Catherijne A. J.
    DRUG DISCOVERY TODAY, 2009, 14 (5-6) : 316 - 320
  • [28] USE OF INTEGRATED PK/PD MODELS FOR SUITABLE UNDERSTANDING OF PRECLINICAL PHARMACOLOGY DATA OF A NEW MOLECULE
    Soengas, I.
    Ortega, I.
    Ortega, F.
    Rodriguez, M.
    Vozmediano, V.
    Calvo, R.
    Orjales, A.
    Lucero, M. L.
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 75 - 75
  • [29] Parameterization of physiologically based pharmacokinetic models based on clinical and preclinical PK data
    Snoeys, Jan
    DRUG METABOLISM REVIEWS, 2016, 48 : 6 - 6
  • [30] Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers
    Yun-fei Li
    Kun Wang
    Fang Yin
    Ying-chun He
    Ji-han Huang
    Qing-shan Zheng
    Acta Pharmacologica Sinica, 2012, 33 : 1424 - 1430
12345